MoFo Life Sciences

November 14, 2023 - Licensing + Commercial
Patent Prosecution Strategies to Avoid Pitfalls in Post-grant Proceedings
By: Ashley E. Sperbeck and Mark D. McBriar Ph.D.
On October 26, 2023, the U.S. Court of Appeals for the Federal Circuit in Monterey Research, LLC v. STMicroelectronics, Inc. [1] affirmed a pair of final written decisions at the Patent Trial and Appeal Board (PTAB)[2] that invalidated challenged patent claims owned by Monterey
... ›
July 05, 2023 - Intellectual Property, Licensing + Commercial, Agtech
Top 10 Considerations for Transactions Involving Alternative Protein Companies
By: Matthew A. Ferry and Sarah E. Bloch Ph.D.
Matthew Ferry and Sarah Bloch authored an article for the Daily Journal discussing the top ten aspects alternative protein companies should consider when planning for and negotiating research and commercial agreements. Read the full article.
... ›
May 10, 2023 - Agtech, Intellectual Property, Licensing + Commercial, United States
IP Implications of USDA Research Collaborations
By: Tina D. Reynolds, Liz Freeman Rosenzweig Ph.D. and Bu Yin Ph.D.
Many stakeholders in the AgTech industry are interested in collaborating with or obtaining funding from the United States Department of Agriculture (USDA), but are unsure what implications such collaborations may have on their intellectual property (IP) obligations, opportunities, and strategy. Here, we summarize key
... ›
April 27, 2023 - AI + Robotics, Licensing + Commercial, Regulatory, Intellectual Property
10 Considerations When Licensing AI for Drug Discovery
By: Stephanie Lynn Sharron and Wolfgang Schönig
While the traditional process of discovering a new drug is long and expensive, artificial intelligence drug development platforms can help reduce time and money by efficiently analyzing vast data sets within the drug discovery process. Researchers can use such AI platforms for identifying new
... ›
March 23, 2023 - Biotech, Pharma, Licensing + Commercial, Asia, Regulatory
China Eyes New Export Controls for Life Sciences Technologies
By: Tyler Xiu, Bu Yin Ph.D., Gordon A. Milner, Chuan Sun and Janet Xiao Ph.D.
China is considering new export restrictions on advanced technologies, including, in particular, in the life sciences sectors. In late December 2022, China’s Ministry of Commerce (“ MOFCOM ”) issued the proposed amendment to the country’s Catalogue of Technologies Prohibited and Restricted for Export (the
... ›
February 23, 2022 - Financing, Licensing + Commercial, Agtech
Quick Guide to JVs in the Alternative Protein Industry
By: Alistair Maughan and Simon Arlington
Investment in the alternative protein industry is surging, and companies are increasingly capitalising on opportunities to partner with each other in this area. Where the partners bring roughly an equal share to the table, these partnerships may be referred to as JVs. JVs are
... ›
January 19, 2021 - Licensing + Commercial, United States, European Union
Top 10 Considerations When Drafting and Negotiating SRAs, with U.S. and EU Perspectives
By: Wolfgang Schönig, Matt Karlyn and Robert Grohmann
Sponsored Research Agreements (SRA) are used by companies to contract a research organization, such as a university, to conduct research and development activities in exchange for fees and the university’s rights to use the results for general research purposes. Care should be taken to
... ›
December 04, 2020 - Licensing + Commercial, Corporate + Venture Capital, COVID-19, Startup
Navigating Transaction and Licensing Issues in a COVID-19 World and Raising Angel Investments
By: Jim Krenn, Matt Karlyn and Michael Ward Ph.D.
Session 2 of the GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start Ups was led by Transactions and Licensing partner Matt Karlyn and focused on how to navigate commercial life sciences transactions and licensing issues in
... ›
November 23, 2020 - Licensing + Commercial, FDA, COVID-19, Intellectual Property
Podcast: Toward a Therapy for COVID-19: The Science and Legal Considerations
By: Janet Xiao Ph.D. and Michael Ward Ph.D.
Researchers around the world are working at record speed to find the best ways to treat and prevent COVID-19. In this last episode of our four-part podcast series, we discuss the science, regulatory framework, and commercial transaction considerations of a COVID-19 therapy. Michael Ward,
... ›
November 03, 2020 - Licensing + Commercial, FDA, COVID-19, Intellectual Property
Podcast: Toward a Vaccine for COVID-19: The Science and Legal Considerations
By: Otis Littlefield Ph.D. and Michael Ward Ph.D.
In this third of a four-part podcast series, we discuss the science, regulatory framework, and commercial transactions considerations of a COVID-19 vaccine. Michael Ward, MoFo partner and global head of the firm’s Life Sciences Group and Patent Group, discusses these issues among others with:
... ›

Topic Archives: Licensing + Commercial

Patent Prosecution Strategies to Avoid Pitfalls in Post-grant Proceedings

By: Ashley E. Sperbeck and Mark D. McBriar Ph.D.

Top 10 Considerations for Transactions Involving Alternative Protein Companies

By: Matthew A. Ferry and Sarah E. Bloch Ph.D.

IP Implications of USDA Research Collaborations

By: Tina D. Reynolds, Liz Freeman Rosenzweig Ph.D. and Bu Yin Ph.D.

10 Considerations When Licensing AI for Drug Discovery

By: Stephanie Lynn Sharron and Wolfgang Schönig

China Eyes New Export Controls for Life Sciences Technologies

By: Tyler Xiu, Bu Yin Ph.D., Gordon A. Milner, Chuan Sun and Janet Xiao Ph.D.

Quick Guide to JVs in the Alternative Protein Industry

By: Alistair Maughan and Simon Arlington

Top 10 Considerations When Drafting and Negotiating SRAs, with U.S. and EU Perspectives

By: Wolfgang Schönig, Matt Karlyn and Robert Grohmann

Navigating Transaction and Licensing Issues in a COVID-19 World and Raising Angel Investments

By: Jim Krenn, Matt Karlyn and Michael Ward Ph.D.

Podcast: Toward a Therapy for COVID-19: The Science and Legal Considerations

By: Janet Xiao Ph.D. and Michael Ward Ph.D.

Podcast: Toward a Vaccine for COVID-19: The Science and Legal Considerations

By: Otis Littlefield Ph.D. and Michael Ward Ph.D.